Our Model

Advancing Therapies
to the Next
Phase

Diode Bio partners with global pharma to unlock the clinical and commercial potential of their underfunded assets — structuring new development options for our Partner's pipeline.

How It Works → Partner With Us
What We Focus On

Assets with Untapped Potential

We look for Phase I & II assets that have compelling science but lack a clear path to full development — and where APAC recruitment and execution speed create a meaningful advantage.

Oncology & Immunology

Phase I & II assets with meaningful clinical potential, but where R&D resource or funding constraints have stalled further development.

Phase 1 · Phase 2

APAC Execution Advantages

Assets where enrollment speed, patient populations, or regulatory pathways in APAC unlock data that Western-only programmes cannot generate efficiently.

Asia · Regional

Maximum Flexibility

Partners retain full ownership optionality. Flexibile agreement structures — not acquisitions — preserve options for our Partners.

Partnership · Optionality
The Platform

Four Integrated Capabilities

Built by operators from J&J, GSK, AstraZeneca and Novartis — supported by Singapore sovereign wealth funds, institutional capital and preferred CRO infrastructure across APAC.

Deep Pharma Expertise

Senior leadership with global clinical execution, corporate development, and BD experience across multiple therapeutic sectors.

Institutional Capital

Singapore-headquartered, sovereign-backed financing. Asset-specific structured deals deployed on a milestone-driven basis.

Global Advisory Network

KOL ecosystem spanning oncology and immunology. Finance advisory team highly experienced with Asia-Pacific structured development models.

APAC Clinical Infrastructure

Preferred CRO relationship with Novotech. Faster recruitment, regional site access, and established regulatory pathways across APAC markets.

Our Process

From Opportunity to Outcome

A structured four-stage approach — disciplined diligence, flexible deal design, and precise APAC execution.

01
Source

Asset Identification

Network-driven deal flow across global pharma. Assets with strong science, clear development rationale, and APAC advantage.

02
Evaluate

Scientific & Strategic Diligence

Deep CMC, clinical, and commercial analysis. Independent advisory review and APAC regulatory pathway assessment.

03
Structure

Deal & Capital Structuring

Co-development agreement preserving full partner optionality. Milestone-based capital deployment with aligned incentives.

04
Execute

APAC Clinical Execution

Preferred CRO infrastructure, regional site activation, and regulatory engagement. Rapid data generation for global programmes.

How We Operate

Discreet by Design

We move quietly. No press releases, no competitive noise — protecting partner relationships and preserving deal optionality throughout the development process.

Standard BD Approach

High Visibility, High Friction

✕
Public announcements signal competitive intent, alerting rivals and elevating asset valuations prematurely.
✕
Broad outreach creates noise across markets and complicates regulatory relationships.
✕
Slow deal timelines driven by large BD team processes and multi-committee approval cycles.
✕
All-or-nothing structures often require full acquisition, eliminating partner upside.
The Diode Bio Way

Silent, Structured, Swift

✓
Confidential process from identification to execution — protecting partner relationships and commercial positioning.
✓
Targeted engagement with relevant APAC regulatory bodies through established relationships, not broad outreach.
✓
Lean decision-making — senior team empowered to move quickly from diligence to term sheet.
✓
Option-based agreement structures preserve full partner ownership optionality at every stage.
Strategic Outcomes

What Partners Gain

Diode Bio creates clinical data, regional optionality, and capital-efficient development milestones — without diluting global rights or requiring upfront commitment.

Accelerated Data Generation

APAC trials run faster — larger, treatment-naive patient populations and streamlined site activation compress timelines significantly.

Preserved Optionality

Partners retain full global rights. Diode Bio holds regional development rights only — structured to protect upstream value at all times.

Capital-Efficient Development

Milestone-based financing with no upfront capital requirement. Aligned incentives from deal close through data readout.

Ph I & IIDevelopment Stage Focus
I & OCore Therapy Areas
APACExecution Hub
100%Partner Optionality Retained

A Different Kind of Development Partner.

Reach out to explore how Diode Bio can unlock value in your pipeline — confidentially, and on your terms.

Get In Touch Meet the Team